Earnings Summary

Cyteir Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2023. On a quarterly growth basis, Cyteir Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Cyteir Therapeutics, Inc.’s net profit jumped 30.67% since last year same period to $-8.4Mn in the Q2 2023. On a quarterly growth basis, Cyteir Therapeutics, Inc. has generated 32.69% jump in its net profits since last 3-months.

Cyteir Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2023. On a quarterly growth basis, Cyteir Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Cyteir Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.3 - a -14.51% fall from last quarter’s estimates.

Cyteir Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.3.

Cyteir Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2023. This indicates that the Cyteir Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.